Ordinare BioPharma Inc, binmetinib, Braftovi, encorafenib, Mektovi, laboratorium Pfizer
Encorafenib cum binimetinib approbatur a FDA ad tractationem cancri metastatici non-miniculi cellulae pulmonis cum BRAF V600E mutatione.
Cibus et medicamentum Administrationis (FDA) approbavit Encorafenib (Braftovi, Array BioPharma Inc., subsidiaria totius Pfizer) et binimetinib (Mektovi, Array BioPharma Inc.) mense Novembri 2023 ut medicamenta quae adhiberi possunt ad t.
Bosulif, Bosutinib, longis myelogenous leukemia, CML, laboratorium Pfizer
Bosutinib pro aegris pediatricis FDA approbatur cum myelogenois leukemia chronicis
Nov 2023: Aegri pediatrici uno anno et supra cum periodo chronica (CP) Ph+ chronica myelogena leukemia (CML), vel nuper praecognita (ND) vel repugnant vel intolerantia (R/I) ad justos priorum, Cibus et medicamentis Admini. .
laboratorium Pfizer, TALAPRO-2, Talazoparib
Talazoparib cum enzalutamide approbatur a FDA pro HRR metastatica gene castratio-repugnans cancer prostatae
July 2023: The Food and Drug Administration cleared talazoparib (Talzenna, Pfizer, Inc.) with enzalutamide for homologous recombination repair (HRR) gene mutations in metastatic castration-resistant prostate cancer (mCRPC). TALAP..
ADVL0912, anaplastic lymphoma discoideum, lymphoma, NCT00939770, laboratorium Pfizer, Xalkori
Crizotinib ab FDA approbatur pro tumore myofibroblastico alK-positivo inflammatorio
Iulii 2022: Crizotinib (Xalkori, Pfizer Inc.) approbata est ab Administratione Cibus et medicamentis (FDA) ad curationem aegrorum adultorum et pediatricorum 1 anno aetatis et seniorum, qui indissolubili dignosci erant, recurrentes.
ALK, B7461006, crizotinib, Lobrrena, lorlatinib, NCT03052608, laboratorium Pfizer, Ventana ALK, Ventana Systems Medicum
Probatus per FDA in Lorlatinib est in treatment of-positivum NSCLC metastatic ALK.
Augusti 2021 : Lorlatinib (Lorbrena, Pfizer Inc.) approbationem regularem accepit FDA aegris cum cancro metastatico non-miniculo cellulae pulmonis (NSCL) cuius tumores lymphoma kinasi anaplastici (ALK) -positivi sunt, prout per FDA-app.
anaplastic lymphoma discoideum, B7461006, CDx Asssay, Cibus et medicamentis Administration, Lobrrena, lorlatinib, NCT03052608, NSCLC, laboratorium Pfizer, Ventana ALK, Ventana Systems Medicum
Lorlatinib est approbata per FDA ad de metastatic ALK, positivum curatio NSCLC
Augusti 2021 : Lorlatinib (Lorbrena, Pfizer Inc.) approbationem regularem accepit FDA aegris cum cancro metastatico non-miniculo cellulae pulmonis (NSCL) cuius tumores lymphoma kinasi anaplastici (ALK) -positivi sunt, prout per FDA-app.
Bharat Biotech, coronavirus, Covaxin, Covid, Vaccinum in covid, Covishield, laboratorium Pfizer
XIX-Hepatitis COVID - Omnia quae voluit scire,
Dr. Julie Gralow respondet queries de COVID-19 vaccine. Quomodo vaccina certa esse possumus si in tam brevi tempore productae et approbatae sint? Communitas medicinae laboratum est ut vaccina COVID-19 valeant.